RT Journal Article
SR Electronic
T1 The Project for Objective Measures Using Computational Psychiatry Technology (PROMPT): Rationale, Design, and Methodology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19013011
DO 10.1101/19013011
A1 Kishimoto, Taishiro
A1 Takamiya, Akihiro
A1 Liang, Kuo-ching
A1 Funaki, Kei
A1 Fujita, Takanori
A1 Kitazawa, Momoko
A1 Yoshimura, Michitaka
A1 Tazawa, Yuki
A1 Horigome, Toshiro
A1 Eguchi, Yoko
A1 Kikuchi, Toshiaki
A1 Tomita, Masayuki
A1 Bun, Shogyoku
A1 Murakami, Junichi
A1 Sumali, Brian
A1 Warnita, Tifani
A1 Kishi, Aiko
A1 Yotsui, Mizuki
A1 Toyoshiba, Hiroyoshi
A1 Mitsukura, Yasue
A1 Shinoda, Koichi
A1 Sakakibara, Yasubumi
A1 Mimura, Masaru
A1 on behalf of the PROMPT collaborators
YR 2019
UL http://medrxiv.org/content/early/2019/11/29/19013011.abstract
AB Background Depressive and neurocognitive disorders are debilitating conditions that account for the leading causes of years lived with disability worldwide. Overcoming these disorders is an extremely important public health problem today. However, there are no biomarkers that are objective or easy-to-obtain in daily clinical practice, which leads to difficulties in assessing treatment response and developing new drugs. Due to advances in technology, it has become possible to quantify important features that clinicians perceive as reflective of disorder severity. Such features include facial expressions, phonic/speech information, body motion, daily activity, and sleep. The overall goal of this proposed study, the Project for Objective Measures Using Computational Psychiatry Technology (PROMPT), is to develop objective, noninvasive, and easy-to-use biomarkers for assessing the severity of depressive and neurocognitive disorders.Methods This is a multi-center prospective study. DSM-5 criteria for major depressive disorder, bipolar disorder, and major and minor neurocognitive disorders are inclusion criteria for the depressive and neurocognitive disorder samples. Healthy samples are confirmed to have no history of psychiatric disorders by Mini-International Neuropsychiatric Interview, and have no current cognitive decline based on the Mini Mental State Examination. Participants go through approximately 10-minute interviews with a psychiatrist/psychologist, where participants talk about non-specific topics such as everyday living, symptoms of disease, hobbies, etc. Interviews are recorded using RGB and infrared cameras, and an array microphone. As an option, participants are asked to wear wrist-band type devices during the observational period. The interviews take place ≤10 times within up to five years of follow-up. Various software is used to process the raw video, voice, infrared, and wearable device data. A machine learning approach is used to predict the presence of symptoms, severity, and the improvement/deterioration of symptoms.Discussion The PROMPT goal is to develop objective digital biomarkers for assessing the severity of depressive and neurocognitive disorders in the hopes of guiding decision-making in clinical settings as well as reducing the risk of clinical trial failure. Challenges may include the large variability of samples, which makes it difficult to extract the features that commonly reflect disorder severity.Trial Registration UMIN000021396, University Hospital Medical Information Network (UMIN)Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; T. Kishimoto reports personal fees from Otsuka, Pfizer, and Dainippon Sumitomo, Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer; KF reports personal fees from Novartis and Mochida, non-financial support from Otsuka; HT is an employee of FRONTEO; TH reports personal fees from Yoishitomi; T. Kikuchi has reports personal fees from Astellas, Dainippon Sumitomo, Eli Lilly, Janssen, MSD, Otsuka, Yoshitomi Yakuhin, Pfizer, and Takeda; JM reports personal fees from Eli Lilly, Janssen, Otsuka, MSD, Shionogi, and Pfizer; MM reports personal fees from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin, and he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura. Other authors have no conflict of interest; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialUMIN000021396Clinical Protocols https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000024677 https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000027146 Funding StatementThis research is supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP18he1102004. The Grant was awarded on Oct. 29, 2015 and ends on Mar. 31, 2019. The funding source did not participate in the design of this study and will not have any hand in the study’s execution, analyses, or submission of results. Japan Agency for Medical Research and Development (AMED) 20F Yomiuri Shimbun Bldg. 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004 Japan Tel: +81-3-6870-2200, Fax: +81-3-6870-2241, Email: jimu-ask@amed.go.jp Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.UMINUniversity Hospital Medical Information NetworkUIuncertainty intervalYLDsyears lived with disabilityHAM-DHamilton Depression Rating ScaleMADRSMontgomery-Asberg Depression Rating ScalePETpositron emission tomographyMRImagnetic resonance imagingMCImild cognitive impairmentMMSEMini-Mental State ExaminationMoCAMontreal Cognitive AssessmentPROMPTProject for Objective Measures Using Computational Psychiatry TechnologyAMEDJapan Agency for Medical Research and DevelopmentDSM-5Diagnostic and Statistical Manual of Mental Disorders, Fifth EditionSCIDStructural Clinical Interview for DSM-5M.I.N.I.Mini-International Neuropsychiatric InterviewRGBred, green, blueUVultravioletISOInternational Organization for StandardizationFedRAMPFederal Risk and Authorization Management ProgramIECInternational Electrotechnical CommissionBDI-IIBeck Depression Inventory, Second EditionF0fundamental frequencyF1, F2, F3first, second, and third formant frequenciesCPPcepstral peak prominenceMFCCmel-frequency cepstrum coefficientsSVRSupport Vector RegressionSVMSupport Vector MachineRFRandom ForestAdaboostAdaptive BoostingAdabagAdaptive BaggingCNNConvolutional Neural NetworksGCNGated Convolutional Neural NetworksBNNBayesian Neural NetworksLSTMLong Short-Term Memory NetworksMARSMotor Agitation and Retardation ScaleMDDMajor depressive disorderBDBipolar disorderYMRSYoung Mania Rating ScalePSQIPittsburgh Sleep Quality IndexCDRClinical Dementia RatingLMWechsler Memory Scale-Revised Logical MemoryCDTClock Drawing TestNPINeuropsychiatric InventoryGDSGeriatric Depression Scale